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Abstract
Background: Quality indicators for the Brazilian cervical cancer screening programme can provide a perspective on
its effectiveness in Brazilian macro-regions and states. The aim of this study was to perform a trend analysis of the
cervical cancer screening program’s quality indicators, according to Brazilian regions and states, from 2006 to 2013.
Methods: Using information from approximately 62,000,000 exams obtained from the Information System of
Cervical Cancer Screening (SISCOLO), joinpoint analysis was used to calculate the Annual Percentage Change (APC).
Results: The estimated number of women in the target age group (25–64 years) who underwent Pap testing over a
three-year interval was lower than that recommended by international guidelines in the North, Northeast and Midwest
regions, and the trends for this indicator remained stationary over the years in all regions of Brazil. Overall, the index of
positivity in Brazilian regions and states is below that preconized by the Brazilian National Cancer Institute (INCA).
Additionally, the frequencies of unsatisfactory cases are in line with international guidelines but above those
preconized by INCA guidelines. All positive cytological diagnoses were lower than those preconized by INCA.
Conclusions: The results show that the cervical cancer screening programme is still far from efficient because most of
the quality indicators in Brazilian regions and states are outside of the parameters preconized by national and
international organizations.
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Background
Cervical cancer is a global public health problem, it is
the fourth most diagnosed cancer in women worldwide
with an estimated 528,000 new cases, and it is the fourth
most frequent cause of cancer death among women
worldwide with 266,000 estimated deaths in 2012. More
than 85% of the new cases and more than 87% of the
deaths from cervical cancer occurred in poor and devel-
oping countries [1].
In Brazil, which is a federation of 26 states and one fed-
eral district that is divided into 5 macro-regions (North,
Northeast, Midwest, Southeast and South) [2], cervical can-
cer is the third most common cancer in women with ap-
proximately 16,400 new cases expected in 2016 [3]. In
2013, cervical cancer was the third most frequent cause of
death by cancer among women [4]. In regional estimates
for 2016, disregarding non-melanoma skin tumours, the
North ranked first with the highest expected incidence
(23.93 cases per 100,000 women), followed by the Midwest
(20.72 cases per 100,000 women), the Northeast (19.49
cases per 100,000 women), the South (15.17 cases per
100,000 women) and finally, the Southeast, which had the
lowest incidence (11.30 cases per 100,000 women) [3]. Re-
garding mortality, the data from 2013 indicate the North
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(Amazon area) had the highest values in the country, with a
rate standardized to the world population of 11.51 deaths
per 100,000 women, followed by the Northeast (5.83 deaths
per 100,000 women), the Midwest (5.63 deaths per 100,000
women), the South (4.39 deaths per 100,000 women) and
the Southeast (3.59 deaths per 100,000 women) [5].
The Brazilian cervical cancer screening programme was
designed in response to the high incidence and mortality
rates in the country and is coordinated by the Brazilian
National Cancer Institute (INCA). The screening method
in Brazil is based on the conventional Pap test, which is
recommended for women between 25 and 64 years old in
a three-year interval after two annual negative tests [6].
In recent years, actions have been taken to improve the
effectiveness of the programme. The Information System of
Cervical Cancer Screening (SISCOLO), created in 1999 by
INCA and the Department of Informatics of the Public
Health System, contains information on all Pap tests col-
lected in the public health system. This information system
was implemented to manage and monitor the cervical can-
cer screening programme [7].
In 2005, the Action Plan for the Control of Cervical and
Breast Cancer proposed the following six strategic
guidelines: i. increased coverage of the target population; ii.
laboratory quality assurance; iii. Strengthening of the infor-
mation system; iv. development of professional training pro-
grammes; v. social mobilization strategies; and vi. research
development [7]. In 2012, to improve the quality and reli-
ability of cytopathological exams, INCA and the Ministry of
Health published a Quality Management Manual for
Cytopathology Laboratory. This manual presents some im-
portant indicators for monitoring laboratory results and
assessing the overall and individual performance [8].
Despite these efforts, the coverage rate for the cervical
cancer screening programme in Brazil, i.e., the number of
women who underwent Pap tests in a three-year period, is
estimated to be below 70%, and some quality indicators of
the programme are below the values preconized by INCA;
e.g., the positivity index [(number of abnormal exams in
the target age group / number of satisfactory exams in the
target age group) × 100] is below the interval 3–10% and
the High-grade Squamous Intraepithelial Lesion (HSIL)
percentage is below the interval 0.5–1.0% [9]. Of note,
many barriers must be overcome to improve the effective-
ness of the cervical cancer screening programme. As Brazil
is a very large country with heterogeneous resources, edu-
cation, health and income, barriers to screening are among
the greatest difficulties to overcome [7, 10]. The differences
in the incidence and mortality of cervical cancer are clear
indicators of the heterogeneity among macro-regions. With
knowledge of the quality indicators for each Brazilian
macro-region and state, it is possible to develop actions to
improve the cervical cancer programme effectiveness. This
study aims to perform a trend analysis for the cervical
cancer screening programme using the following quality in-
dicators: productivity rate, percentage of unsatisfactory
exams, positivity index, Atypical Squamous Cells of
Undetermined Significance (ASC-US) percentage, HSIL
percentage and ASC/SIL ratio, by Brazilian regions and
states, from 2006 to 2013, based on data collected from
SISCOLO.
Methods
This study is a time series analysis of the quality indi-
cators for the Brazilian cervical cancer screening
programme, which was evaluated by Brazilian region
and state. Data on the cytopathological exams per-
formed in the public health system, from January
2006 to December 2013 (n = 81,322,750), which are
publicly available at SISCOLO (http://www2.datasus.-
gov.br/DATASUS/index.php), were collected by state
(place of collection) and age of the women who vol-
untarily participated in the opportunistic Governmen-
tal Brazilian programme of cervical cancer prevention.
Data regarding the number of females were obtained
from Department of Informatics of the Public Health
System (http://tabnet2.datasus.gov.br/cgi/deftohtm.ex-
e?idb2013/a01.def ) from 2006 and 2012. This study
was approved by the Ethics Committee of the Barre-
tos Cancer Hospital.
The following quality indicators were determined for
women aged 25 to 64 years: (1) productivity rate; (2)
percentage of unsatisfactory exams; (3) positivity index;
(4) ASC-US percentage; (5) HSIL percentage; and (6)
ASC/SIL ratio. The formulas used to obtain the indica-
tors are shown in Table 1.
Data processing and statistical analysis
R Software (R Development Core Team. R: A language
and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria) and Micro-
soft Excel 2010 (Microsoft Corporation 2010) were used
to organize the collected data, create new spreadsheets
and calculate the quality indicators.
The Annual Percentage Change (APC) for each indica-
tor was calculated using the Joinpoint Regression Pro-
gram Version 4.1.1 (August 2014; Statistical Methodology
and Applications Branch, Surveillance Research Program,
National Cancer Institute). The Monte Carlo permuta-
tions method was used to test for the significance and
natural logarithm of the rates with y =mx + b (where y =
ln (rate) and x = calendar year); then, APC = 100×(em-1)
was used to determine the APC. Each significant point in-
dicates an increase or decrease in the rate [11]. To de-
scribe the linear trend for each period, the APC values
and respective 95% confidence interval (95% CI) for each
trend were computed.
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Results
From 2006 to 2013, 62,397,698 out of a total of 81,322,750
(76.7%) cytopathological exams were performed for Brazil-
ian women in the screening target age group (25–64 years).
Considering the prevalence ratios using the South as a
reference, because this region has the highest percentage of
municipalities with very high and high HDI values [10], the
number of unsatisfactory exams in the North and North-
east was 4-fold higher, while the number of abnormal
exams in the Midwest and Southeast was approximately
1.6-fold higher than that observed in the South. The num-
ber of exams with ASC-US results in the Southeast region
was 1.7-fold higher than that observed in the South, and
only the Northeast region had fewer ASC-US exams than
the South region. When looking at HSIL, the number of
exams detected in the North and Midwest was approxi-
mately 1.7-fold higher than that in the South (Table 2).
Table 3 shows the APC values for the quality indica-
tors by Brazilian macro-region. Fig. 1 shows the time
series of the quality indicators from each Brazilian
macro-region. Additional file 1: Tables S1-S6 show the
values and APC values of the quality indicators by Bra-
zilian state from 2006 to 2013.
North
In the North, in the period under study, 3620,39 out of a
total of 4,728,920 (76%) exams were performed in the
target age group.
The trend for the productivity rate remained station-
ary; the percentage of unsatisfactory exams significantly
decreased by 11.3% per year from 2006 to 2011, and sig-
nificantly increased by 39.7% per year from 2011 to
2013. The positivity index remained constant. The ASC-
US percentage suffered a significant decrease of 7.7% per
year from 2006 to 2010, and it remained stable from
2010 to 2013. The HSIL percentage remained stable
from 2006 to 2010, and it significantly increased by
10.5% per year from 2010 to 2013, while an increase of
5.6% per year was observed in the ASC/SIL ratio during
the study period.
Looking at the quality indicators in states in the North,
the behavioural trend was very similar, except in Ror-
aima, where there was a significant decrease in the prod-
uctivity rate from 2011 to 2013, and a significant
increase in the number of unsatisfactory exams; add-
itionally, in Amazonas and Pará, the positivity index and
ASC-US percentage significantly increased.
Northeast
In the period under study, 16,541,659 out of a total of
21,798,808 (75.9%) exams were performed in the target
age group in the Northeast.
The productivity rate suffered a significant decrease of
3.5% per year; there were no significant changes in the
percentage of unsatisfactory exams and positivity index.
The ASC-US percentage significantly increased by 2.8%
Table 1 Formulas to calculate quality indicators and reference values preconized by the Brazilian National Cancer Institute
Indicators Calculation Reference Values
Productivity rate (%)a number of exams performed ð25‐64Þnumber of women ð25‐64Þ  100 Not available
% Unsatisfactory number of unsatisfactory exams ð25‐64Þnumber of exams performed ð25‐64Þ  100 1% (Average of the collected exams in Brazil in 2010)
% Positivity index number of abnormal exams ð25‐64Þnumber of satisfactory exams ð25‐64Þ  100 3–10%
% ASC-US number of ASC‐US exams ð25‐64Þnumber of satisfactory exams ð25‐64Þ  100 Not available
% HSIL number of HSIL exams ð25‐64Þnumber of satisfactory exams ð25‐64Þ  100 0 5–1 0% (USA, 0.5%; Canada, 0.6%; UK, 1.1%; Norway, 1.1%)
ASC/SIL ratio number of ASC exams ð25‐64Þnumber of SIL exams ð25‐64Þ <3
Abbreviations: ASC-US Atypical Squamous Cells of Undetermined Significance, ASC Atypical Squamous Cells, HSIL High-grade Squamous Intraepithelial Lesion, SIL
Squamous Intraepithelial Lesion
aNumber of women unavailable for 2013
Table 2 Prevalence and prevalence ratio from 2006 to 2013, comparing the quality indicators using the South as a reference
Macro-region Productivity ratea Unsatisfactory exams Positivity index ASC-US HSIL
P (%) PR P (%) PR P (%) PR P (%) PR P (%) PR
South 17.08 1.0 (ref) 0.41 1.0 (ref) 1.91 1.0 (ref) 0.90 1.0 (ref) 0.26 1.0 (ref)
Southeast 16.42 0.96 0.65 1.59 2.98 1.56 1.53 1.70 0.28 1.08
Midwest 15.64 0.92 0.97 2.37 3.12 1.64 1.26 1.39 0.45 1.72
Northeast 17.02 0.99 1.89 4.60 2.17 1.14 0.80 0.88 0.29 1.12
North 14.13 0.83 1.64 3.98 2.60 1.37 0.92 1.02 0.43 1.67
Abbreviations: ASC-US Atypical Squamous Cells of Undetermined Significance, HSIL High-grade Squamous Intraepithelial Lesion, P prevalence, PR prevalence ratio,
ref. reference value
aOnly data until 2012 were available,
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per year, and the HSIL percentage remained stable over
the years, while the ASC/SIL ratio significantly increased
by 7.3% per year.
Analysing the quality indicators for the states in the
Northeast, a significant decrease in the productivity
rate was observed in Ceará, Pernambuco and Rio
Grande do Norte. In Ceará, the percentage of unsatis-
factory exams significantly decreased, and in Alagoas,
the positivity index significantly decreased from 2006
to 2011, while it significantly decreased in Paraiba
from 2011 to 2013. The HSIL percentage significantly
decreased in Maranhão from 2006 to 2011 and in
Sergipe during the study period.
Midwest
In the Midwest, during the period under study,
4,408,614 out of a total of 5,713,757 (77.2%) exams were
performed in the target age group.
From 2006 to 2008, the productivity rate significantly in-
creased by 15.1% per year, followed by a significant decrease
of 5.7% per year from 2008 to 2012. In the percentage of
unsatisfactory exams from 2006 to 2010, there was a signifi-
cant decrease of 14.9% per year, and from 2010 to 2013, an
increase was observed, but it was not significant. The posi-
tivity index remained constant without significant changes
over the years under study. The ASC-US percentage de-
creased from 2006 to 2010 and increased from 2010 to
Table 3 Quality indicator trends by Brazilian macro-region from 2006 to 2013
Macro-region Indicator Trend 1 APC CI 95% Trend 2 APC CI 95%
North Productivity rate (%)a 2006–2012 − 1.7 −8.1,5.2
Unsatisfactory exams (%) 2006–2011 − 11.3* − 17.5,-4.7 2011–2013 39.7* 1.3,92.7
Positivity index (%) 2006–2010 −9.6* −15.3,-3.6 2010–2013 10.3 −0.3,22.1
ASC-US (%) 2006–2010 −7.7* −14.0,-1.0 2010–2013 11.8 0.0,25.1
HSIL (%) 2006–2009 −13.4 −25.2,0.3 2009–2013 10.5* 0.7,21.2
ASC/SIL 2006–2013 5.6* 3.0,8.3
Productivity rate (%)a 2006–2012 − 3.5* − 6.4,-0.5
Northeast Unsatisfactory exams (%) 2006–2013 0.1 −1.7,1.9
Positivity index (%) 2006–2013 0.6 −2.4,0.9
ASC-US (%) 2006–2013 2.8* 1.2,4.4
HSIL (%) 2006–2013 −1.1 −3.5,1.5
ASC/SIL 2006–2013 −4.7 −9.9,0.9
Productivity rate (%)a 2006–2008 15.1* 0.2,32.2 2008–2012 −5.7* −9.7,-1.4
Midwest Southeast Unsatisfactory exams (%) 2006–2010 −14.9* −27.1,-7.5 2010–2013 5.9 −7.2,20.8
Positivity index (%) 2006–2010 −5.3 −11.9,1.9 2010–2013 7.4 −4.3,20.5
ASC-US (%) 2006–2010 −6.8 −15.8,3.3 2010–2013 9.3 −7.1,28.6
HSIL (%) 2006–2013 1.0 −0.8,2.9
ASC/SIL 2006–2011 0.3 −2.1,2.7 2011–2013 12.7* 1.3,25.4
Productivity rate (%)a 2006–2012 0.8 −0.7,2.3
Unsatisfactory exams (%) 2006–2013 −1.5 −5.2,2.4
Positivity index (%) 2006–2013 0.6 −1.3,2.4
ASC-US (%) 2006–2013 2.0 −0.5,4.6
HSIL (%) 2006–2013 −3.7* −6.8,-0.4
ASC/SIL 2006–2013 7.4* 4.1,10.0
Productivity rate (%)a 2006–2012 0.3 −3.6,4.4
South Unsatisfactory exams (%) 2006–2013 −3.5* −6.1,-0.9
Positivity index (%) 2006–2013 0.6 −1.3,2.6
ASC-US (%) 2006–2013 0.6 −2.9,4.2
HSIL (%) 2006–2013 −1.8 −4.5,1.0
ASC/SIL 2006–2013 4.7* 0.5,8.9
Abbreviations: APC Annual Percentage Change, ASC Atypical Squamous Cells, ASC-US Atypical Squamous Cells of Undetermined Significance, CI confidence interval,
HSIL High-grade Squamous Intraepithelial Lesion SIL Squamous Intraepithelial Lesion
*APC is significantly different from 0 (P < 0.05)
aOnly data until 2012 were available
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2013, but neither change was significant. The HSIL per-
centage remained constant over the years under study, and
there was a significant increase of 12.7% per year in the
ASC/SIL ratio from 2011 to 2013.
In the Midwest states, the productivity rate remained
constant, except in Goiás, where it significantly de-
creased from 2008 to 2012. In the same state, the per-
centage of unsatisfactory exams, positivity index, HSIL
percentage, and ASC/SIL ratio significantly increased. In
the remaining states, the quality indicators showed the
same behaviour observed in the Midwest.
Southeast
In the Southeast, in the period under study, 28,161,388
out of a total of 36,675,852 (76.8%) exams were per-
formed in the target age group.
The productivity rate, percentage of unsatisfactory
exams, positivity index and ASC-US percentage
remained constant over the years under study. The HSIL
percentage significantly decreased by 3.5% per year,
while the ASC/SIL ratio increased by 7.4% per year.
In the states of the Southeast, São Paulo experienced a
significant increase in the productivity rate. Espírito
Santo suffered a significant decrease in the percentage of
unsatisfactory exams; the positivity index significantly
increased, while there was a significant decrease from
2006 to 2008 and a significant increase from 2008 to
2013 in Rio de Janeiro. The HSIL percentage remained
constant in all the Southeast states, and the same behav-
iour was observed in the ASC/SIL ratio in the Southeast
region and states.
South
In the period under study, 9,665,640 out of a total of
12,405,413 (77.9%) exams were performed in the target
age group, in the South.
The productivity rate remained constant. The percent-
age of unsatisfactory exams showed a significant de-
crease of 3.5% per year. The positivity index, ASC-US
percentage and HSIL percentage remained constant,
while the ASC/SIL ratio significantly increased by 5.4%
per year during the study.
Fig. 1 Time series of the quality indicators by Brazilian macro-region from 2006 to 2013. a Productivity rate; b % Unsatisfactory exams; c Positivity
index; d % ASC-US; e % HSIL; f ASC/SIL. ASC, Atypical Squamous Cells; ASC-US, Atypical Squamous Cells of Undetermined Significance; HSIL, High-
grade Squamous Intraepithelial Lesion; SIL, Squamous Intraepithelial Lesion
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In the states of the South, the quality indicators
showed the same behavioural trend as that observed in
the entire South.
Discussion
In this study, when looking at the productivity rate,
which is the ratio between the number of Pap tests and
the number of women in the target age (25–64 years),
over the period under study, the South and Northeast
had the highest percentage, with approximately 17%.
The opposite was observed in the North, with only 14%.
In a previous study, the trend for the productivity rate in
Brazil was reported to remain stationary over the years
[9]. In the present study, similar results were observed
in all the Brazilian regions, except the Northeast, where
a significant decrease in the productivity rate was ob-
served over the years under study, and the Midwest,
where a significant increase from 2006 to 2008 and a
significant decrease from 2008 to 2013 were observed.
To use the productivity rate as an estimate of the cover-
age rate, we should consider the following aspects. First,
SISCOLO only provides the overall number of exams
and not the number of women who underwent screen-
ing. Second, the exams include all Pap tests and not only
the first level screening tests (which can generate many
follow-up Pap tests). Third, the Brazilian guidelines rec-
ommend a three-year screening interval, but a signifi-
cant number of women with normal Pap tests undergo
screening more than once every three years [12], which
can result from overuse of the Pap test by physicians, as
well as a lack of women’s knowledge about Pap test peri-
odicity [13]. Of note, according to data from the Minis-
try of Health from 2012 and 2013, approximately 50% of
the Pap tests in Brazil were conducted on an annual
basis, and only 10% were conducted in a three-year
interval [14]. Fourth, the percentage of women in the
target age group in Brazil with private health insurance
during the study period was approximately 25%. The
number, which changes according to the region, was as
follows: 11.3% in the North, 12.4% in the Northeast,
18.1% in the Midwest, 24.5% in the South and 38.1% in
the Southeast [15]. Importantly, data from these exams
were not included in SISCOLO. Considering these
aspects, the overestimated coverage indexes for the
Brazilian regions, using three times the average of the
productivity rate in the period under study plus the per-
centage of women with private health insurance are as
follows: North, 54%; Northeast, 64%; Midwest, 65%;
South, 76% and Southeast, 87%, stressing that a consid-
erable percentage of women underwent a Pap test on an
annual basis. Therefore, it is plausible that a significant
number of Brazilian women do not undergo a Pap test.
According to the World Health Organization, with a
screening coverage for the target population of at least
80%, combined with proper diagnosis and treatment, it
is possible to reduce the incidence of invasive cervical
cancer by as much as 60% to 90% [16].
It is important to note that each macro-region and
state has its peculiarities. The North is one of the poor-
est regions and has the large socio-economic differences
between rural and urban areas. Additionally, it has a
high frequency of riparian communities (Amazon forest),
whose source of livelihood is fishing, with a high rate of
illiteracy and with people living far from the main health
care centres, leading to a low coverage rate [17, 18]. In
this study, the northern region had many quality indica-
tors with inflection points. This observation may be the
result of cervical cancer screening intensification actions
in this region, initiated in 2009, to combat the high inci-
dence and mortality rates observed in this region [7]. It
was observed that the percentages of unsatisfactory sam-
ples were within those recommended by the WHO (<
5%), but they are above the target set by INCA (< 1%),
and the significant increase in unsatisfactory samples
since 2011 should be emphasized. This increase is
mainly associated with problems in sample collection
and preservation, but it might also be a result of the re-
gional training activities performed to qualify profes-
sionals, who may have become more stringent in sample
interpretation. In 2009, there was an increase in the de-
tection of HSIL in this region, and this increased detec-
tion of intraepithelial lesions of high grade can be
explained by both the increase in Pap testing performed
in women who were not previously undergoing screen-
ing and/or by the development of cytotechnologist and
cytopathologist training activities. Despite the increase
in HSIL detection, the values were still below the level
recommended by INCA (0.5–1.0%) as the values for the
positivity index (3–10%). These results strongly suggest
that the high incidence and mortality rates in this region
are a consequence of failure to detect precursor lesions,
and this observation can be the result of a high number
of false negative cases or non-realization of cytological
exams. Of note, it is concerning that in the states of
Acre, Amapá and Rondônia, these indicators had even
lower values than those observed in the region. By con-
trast, the state of Roraima presented values for these two
last indicators within the recommended values.
The Northeast region has the lowest socio-economic
indicators of the country and presents the highest
illiteracy rate in Brazil in 2010 (17.6% of people 10 years
or older) [19], which may hinder cervical cancer screen-
ing. The productivity rate in the period under study de-
creased in this region, as well as in the states of Ceará,
Pernambuco and Rio Grande do Norte [20]. Intriguingly,
the productivity rate values over time were similar to the
ones observed in the South, which is a more developed
region. It is important to emphasize the low values for
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the productivity rate observed in Maranhão, which has
one of the highest estimated incidence rates for cervical
cancer in Brazil, with an incidence of 28.57 new cases
per 100,000 women [3]. A significant decrease was ob-
served in the proportion of unsatisfactory exams in the
state of Ceará, which had values within those preconized
by INCA (< 1%), unlike the Northeast region and other
states of this region. The positivity index values for the
Northeast region are still far from those recommended
by INCA (3–10%), but the states of Maranhão and Rio
Grande do Norte had values within the 3–10% range.
When looking at HSIL, the true precursor lesion of
cervical cancer, a significant decrease was observed in
Maranhão and Sergipe, and the values in the region and
all states were below the preconized range (0.5–1.0%).
In the Midwest, an increase in the productivity rate
was observed from 2006 to 2008; however, this trend
changed to a decrease in 2008 (until 2013), which is pos-
sibly due to policy modifications associated with the pol-
itical change. A significant reduction in unsatisfactory
exams was observed from 2006 to 2010, without changes
in subsequent periods, except for an isolated peak in
2011. The percentage of unsatisfactory exams in the last
2 years of the study was low (< 1%).
The Southeast and South are very similar regions where
socioeconomic development and facilities are more com-
mon [2]. In these regions, there were no significant
changes in the productivity rate, which suggests that there
were no policies implemented to increase women’s adher-
ence to Pap testing. The HSIL percentage, approximately
0.3%, was very similar in the two regions; however, the
values remained constant in the South and significantly
decreased in the Southeast. In England and the United
States of American, the precursor lesions are observed in
1.3% [21] and 0.5% [22], respectively. We highlight the
values for HSIL observed in Rio de Janeiro (0.5%), which
were discrepant from those of the remaining states, while
they were within the INCA recommended range. The re-
duction in HSIL during the study period in the Southeast,
in contrast to the increase observed in the North, may be
due to a decrease in the prevalence of HPV or an effect of
the prevention programmes in the region. The decrease in
HSIL in the Southeast is in accordance with a previous
Brazilian study showing a HSIL reduction in women over
30 years of age because of the high percentage of women
who repeat Pap tests on an annual basis [23]. Another in-
teresting observation was the decrease in unsatisfactory
exams in the South, showing an improvement in the
smear quality. Finally, in the Southeast and South, there
was an increase in the ASC/SIL ratio due to the increase
in Atypical Squamous Cells that could not rule out High-
grade squamous intraepithelial lesions (ASC-H), and there
was a decrease in the detection of Low-grade Squamous
Intraepithelial Lesions (LSIL) (data not shown). This
profile is typical of a screening performed in a population
with older women who have a lower prevalence of LSIL
and a higher prevalence of ASC.
Although some studies report a decrease in the in-
cidence of and mortality from cervical cancer in
Brazil, this decrease only occurs in the more devel-
oped areas [24]. Considering the high incidence of
and mortality from cervical cancer in the North and
Northeast, accompanied by a low positivity index and
HSIL percentage, we can speculate that there are
problems with detecting severe abnormalities in these
regions. This study suggests that, despite efforts to
improve the identification of cervical carcinoma pre-
cursor lesions, the morbidity and mortality related to
this type of cancer does not significantly decrease in
low-resource settings when depending only on cyto-
logical screening opportunistic programmes.
The data presented in this study are in line with
previous studies that show that quality indicators for
laboratories that provide services for SUS in several
states and regions of Brazil are, in most cases, outside
of the parameters preconized by the Ministry of
Health [25, 26]. Additionally, the prevalence rates for
the cytopathological results are different among re-
gions, possibly due to differences in the diagnostic
performance of the screening programme, which
could be related to the exam quality [27].
SUS, which financially supports clinical and cytological
examination as well as colposcopy, is importantly af-
fected by the ineffectiveness of results over time and ur-
gently needs to change. Therefore, it is important for
public health authorities to review their procedures for
cervical cancer prevention actions and optimize SUS re-
sources for such purposes, while also improving the
quality of technical procedures and human resource
training. In response, cancer control policies should
consider the differences in access to care and the socio-
economic characteristics of each region [28]. The next
step is likely the implementation of an organized
population-based cervical cancer screening programme,
strengthening the continued education of cytotechnolo-
gists, extensive training, good laboratory infrastructure,
and standardization of quality control. SISCOLO could
be an important tool to drive the success of Brazilian
cervical cancer screening; however, the Brazilian oppor-
tunistic screening programme has some chronic weak-
nesses, one of which is the failure to provide a realistic
number of women effectively undergoing the Pap test.
Currently, SISCOLO only provides the overall number
of tests that were performed, which does not allow for
calculation of the real coverage rate. In addition, SIS-
COLO data only refer to women under the National of
Health System (SUS) and do not include women who
use supplementary health services [6]. When collecting
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information from SISCOLO, we observed that there are
some incomplete data (e.g., 2013 data from the state of
Amapá), which possibly results from a flow of informa-
tion among institutions that is not yet well-established.
To overcome the mentioned limitations, the government
is implementing the Cancer Information System (SIS-
CAN), a web platform that integrates the information
system for cervical (SISCOLO) and breast (SISMAMA)
cancer screening programmes. The integration of this
system with a not-yet-implemented National Health
Registry and a module that will convene women regis-
tered in the SUS to perform the screening tests accord-
ing to the recommended periodicity and age group [29]
is expected to increase the coverage rate.
Finally, inclusion of HPV testing in a cervical can-
cer screening programme should be considered, be-
cause HPV testing detects cervical intraepithelial
neoplasia lesions with higher sensitivity than the Pap
test. Moreover, it is less prone to variation due to hu-
man interpretation of the test, although implementa-
tion of HPV testing also implies professional training
and still demands colposcopic resources [30–32]. Des-
pite those problems, HPV testing overcomes the lo-
gistic and training problems intrinsically related to
cytology and allows for longer screening intervals. Im-
portantly, one should keep in mind the recent break-
through in cervical cancer prevention, which is the
introduction of HPV vaccines. The use of vaccines
promises to modify the burden of cervical cancer in-
cidence and mortality [33].
In addition to those previously discussed, this study
has some limitations. Histological data were not avail-
able, limiting the sensitivity of the results and conclu-
sions. In addition, the SISCOLO platform is not able
to distinguish screening from follow up exams or the
round of screening. Although most of the Pap tests
registered in SISCOLO are performed for screening
purposes, we cannot estimate the proportion of exams
performed for other reasons. In addition, no explan-
ation has been found for the variations in some indi-
cators, which are mainly related to states (e.g. HSIL
percentage in Pará state).
Conclusion
In conclusion, this study showed that the cervical
cancer screening programme is still far from efficient
because most quality indicators in the Brazilian re-
gions and states are outside of the parameters recog-
nized by the Ministry of Health and International
Organizations. Additionally, the trends do not show
an improvement in the quality indicators from 2006
to 2013, suggesting that the current cervical cancer
screening programme requires adjustment to achieve
adequate efficiency.
Additional file
Additional file 1: Table S1. Productivity rate (%) values and trends in
Brazil regions and states from 2006 to 2013. Table S2. Unsatisfactory
exams (%) and trends in Brazil regions and states from 2006 to 2013.
Table S3. Positivity index (%) and trends in Brazil regions and states
from 2006 to 2013. Table S4. ASC-US values (%) and trends in Brazil
regions and states from 2006 to 2013. Table S5. HSIL values (%) and
trends in Brazil regions and states from 2006 to 2013. Table S6.
ASC/SIL ratio values and trends in Brazil regions and states from
2006 to 2013. (DOCX 72 kb)
Abbreviations
APC: Annual Percentage Change; ASC: Atypical Squamous Cells; ASC-
H: Atypical Squamous Cells that could not rule out High-grade squamous
intraepithelial lesions; ASC-US: Atypical Squamous Cells of Undetermined
Significance; HSIL: High-grade Squamous Intraepithelial Lesion; INCA: Brazilian
National Cancer Institute; LSIL: Low-grade Squamous Intraepithelial Lesion;
SIL: Squamous Intraepithelial Lesion; SISCOLO: Information System of Cervical





Availability of data and materials
The dataset used and analysed in the present study is available in the public
database DATASUS (http://www2.datasus.gov.br/DATASUS/index.php).
Authors’ contributions
RFAC conceived and designed the study, analysed the data and wrote the
paper. AL-F conceived and designed the study, read and criticized the paper.
FLV helped conduct the literature review and read and criticized the paper.
CP helped conduct the literature review and read and criticized the paper.
LCZ conceived and designed the study and read and criticized the paper,
and JHF conceived and designed the study, analysed the data and wrote
the paper. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Barretos Cancer





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Graduate Program on Oncology, Barretos Cancer Hospital, Barretos, São
Paulo 14784-400, Brazil. 2Barretos School of Health Sciences Dr. Paulo Prata –
FACISB, Avenida Loja Maçonica Renovadora 68, N° 100, Bairro Aeroporto,
Barretos, SP 14785-002, Brazil. 3Research and Teaching Institute, Barretos
Cancer Hospital, Barretos, São Paulo 14784-400, Brazil. 4Molecular Oncology
Research Center, Barretos Cancer Hospital, Barretos, São Paulo 14784-400,
Brazil. 5Laboratory of Medical Investigation (LIM 14), Faculty of Medicine São
Paulo University, FMUSP, São Paulo 01246-903, Brazil. 6Life and Health
Sciences Research Institute, ICVS, School of Health Sciences, Uminho
University, 4710 Braga, Portugal. 7ICVS/3B’s - PT Government Associate
Laboratory, 4710 Braga/Guimarães, Portugal. 8School of Medical Sciences,
Women’s Hospital CAISM, Unicamp, Campinas, São Paulo 13081-940, Brazil.
Costa et al. BMC Cancer  (2018) 18:126 Page 8 of 9
Received: 24 May 2017 Accepted: 24 January 2018
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
2. Brasil. Instituto Brasileiro de Geografia e Estatística: Brasil em Síntese. In.
https://brasilemsintese.ibge.gov.br/; 2015. Accessed 12 May 2016.
3. Brasil. Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes
da Silva: Estimativa 2016. Incidência de Câncer no Brasil. Rio de Janeiro. INCA;
2016.
4. Brasil. Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes
da Silva: Estimativa 2014. Incidência de Câncer no Brasil. Rio de Janeiro. INCA;
2013.
5. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes
da Silva: Atlas de Mortalidade por Câncer. In. https://mortalidade.inca.gov.
br/MortalidadeWeb/; 2014. Accessed 20 July 2016.
6. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes
da Silva. Coordenação Geral de Ações Estratégias. Divisão de Apoio à Rede
de Atenção Oncológica: Diretrizes Brasileiras para o Rastreamento do
Câncer do Colo do Útero. Rio de Janeiro: INCA; 2011.
7. Brasil. Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes
da Silva. Programa Nacional de Controle do Câncer do Colo do Útero. Rio
de Janeiro: INCA; 2011.
8. Brasil. Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes
da Silva. Coordenação Geral de Prevenção e Vigilância. Divisão de Detecção
Precoce e Apoio à Organização da Rede: Manual de Gestão da Qualidade
para Laboratórios de Citopatologia, vol. 188. Rio de Janeiro: INCA; 2012.
9. Costa RF, Longatto-Filho A, Pinheiro C, Zeferino LC, Fregnani JH. Historical
analysis of the Brazilian cervical cancer screening program from 2006 to
2013: a time for reflection. PLoS One. 2015;10(9):e0138945.
10. The United Nations Development Programme PNUD Brasil - Programa das
Nações Unidas para o desenvolvimento: Atlas do desenvolvimento humano
no Brasil. In. http://www.atlasbrasil.org.br/2013/pt/download/. Accessed 12
Oct 2016.
11. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint
regression with applications to cancer rates. Stat Med. 2000;19(3):335–51.
12. Freitas RA, Carvasan GA, Morais SS, Zeferino LC. Excessive pap smears due
to opportunistic cervical cancer screening. Eur J Gynaecol Oncol. 2008;29(5):
479–82.
13. Vale DB, Morais SS, Pimenta AL, Zeferino LC. Assessment of the cervical
cancer screening in the family health strategy in Amparo, Sao Paulo state,
Brazil. Cad Saude Publica. 2010;26(2):383–90.
14. Brasil. Ministério da Saúde, Instituto Nacional de Câncer José Alencar Gomes
da Silva. Monitoramento das ações de controle dos cânceres do colo do
útero e de mama. Bol Inf Detecção Precoce. 2014;1:1–8.
15. Brasil. Agência Nacional de Saúde Suplementar: ANS Tabnet - Informações
em Saúde Suplementar: Benificiários. In. http://www.ans.gov.br/anstabnet/
cgi-bin/tabnet?dados/tabnet_tx.def. Accessed 23 May 2016.
16. World Health Organization. National Cancer Control Programmes: policies
and managerial guidelines. 2nd ed. Geneve: WHO; 2002.
17. Pinho AA, França Junior I, Schraiber LB, D'Oliveira AFPL. Cobertura e
motivos para a realização ou não do teste de Papanicolaou no Município
de São Paulo. Cad Saude Publica. 2003;19(Supl.2):S303–13.
18. Correa MD, Silveira DS, Siqueira FV, Facchini LA, Piccini RX, Thume E, Tomasi
E. Pap test coverage and adequacy in the south and northeast of Brazil. Cad
Saude Publica. 2012;28(12):2257–66.
19. Brasil. Instituto Brasileiro de Geografia e Estatística: Sinopse do censo
demográfico. In. https://censo2010.ibge.gov.br/sinopse/index.php?dados=
p6&uf=00; 2010. Accessed 18 Oct 2016.
20. Albuquerque KM, Frias PG, Andrade CL, Aquino EM, Menezes G, Szwarcwald CL.
Pap smear coverage and factors associated with non-participation in cervical
cancer screening: an analysis of the cervical cancer prevention program in
Pernambuco state, Brazil. Cad Saude Publica. 2009;25(Suppl 2):S301–9.
21. Screening and Immunisations Team. Health and social care information
center: cervical screening Programme: England Statistics for 2014–15. NHS;
2015.
22. Eversole GM, Moriarty AT, Schwartz MR, Clayton AC, Souers R, Fatheree LA,
Chmara BA, Tench WD, Henry MR, Wilbur DC. Practices of participants in the
college of american pathologists interlaboratory comparison program in
cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331–5.
23. Vale DB, Westin MC, Zeferino LC. High-grade squamous intraepithelial lesion
in women aged <30 years has a prevalence pattern resembling low-grade
squamous intraepithelial lesion. Cancer Cytopathol. 2013;121(10):576–81.
24. Girianelli VR, Gamarra CJ, Azevedo e Silva G. Disparities in cervical and
breast cancer mortality in Brazil. Rev Saude Publica. 2014;48(3):459–67.
25. Thuler LSC, Zardo LM, Zeferino LC. Perfil dos laboratórios citopatológicos do
Sistema Único de Saúde. J Bras Patol Med Lab. 2007;43:12.
26. Tobias AHG, Amaral RG, Diniz EM, Carneiro CM. Quality indicators of cervical
Cytopathology tests in the public Service in Minas Gerais, Brazil. Rev Bras
Ginecol e Obstet. 2016;38:65–70.
27. Discacciati MG, Barboza BM, Zeferino LC. Why does the prevalence of
cytopathological results of cervical cancer screening can vary significantly
between two regions of Brazil? Rev Bras Ginecol Obstet. 2014;36(5):192–7.
28. Vale DB, Sauvaget C, Muwonge R, Ferlay J, Zeferino LC, Murillo R,
Sankaranarayanan R. Disparities in time trends of cervical cancer mortality
rates in Brazil. Cancer Causes Control. 2016;27(7):889–96.
29. Silva DSM, Silva AMN, Brito LMO, Gomes SRL, Nascimento MDS, Chein MBC.
Rastreamento do câncer do colo do útero no Estado do Maranhão, Brasil.
Ciênc saúde coletiva. 2014;19:1163–70.
30. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh
AM, Hingmire S, Malvi SG, Thorat R, Kothari A, et al. HPV screening for
cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.
31. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A,
Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, et al. Efficacy of human
papillomavirus testing for the detection of invasive cervical cancers and
cervical intraepithelial neoplasia: a randomised controlled trial. Lancet
Oncol. 2010;11(3):249–57.
32. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A,
Ratnam S, Coutlee F, Franco EL, Canadian Cervical Cancer Screening Trial
Study G. Human papillomavirus DNA versus Papanicolaou screening tests
for cervical cancer. N Engl J Med. 2007;357(16):1579–88.
33. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact
of HPV vaccination on the accuracy of cervical cancer screening: the need
for a paradigm change. Arch Med Res. 2009;40(6):478–85.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Costa et al. BMC Cancer  (2018) 18:126 Page 9 of 9
